Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Harrow to $65 from $45 and keeps a Buy rating on the shares. The relaunch of Triesence is expected to be highly accretive to the company, as there are substantial commercial synergies with their commercial strategy for Iheezo, the analyst tells investors in a research note. The firm is now modeling Triesence contribution in Q4, which previously began contribution in 1Q25 in its model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow announces relaunch of TRIESENCE for vitrectomy visualization, inflamation
- Harrow announces expansion of corporate headquarters in Nashville
- Harrow Health Unveils Performance Strategy to Investors
- Harrow price target raised to $45 from $30 at Craig-Hallum
- Harrow price target raised to $50 from $29 at B. Riley